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Background: Two pyridine derivatives were 
identified as promising drug candidates in animal 
models of Chagas disease. 
Results: They were tested as sterol 14α-
demethylase (CYP51) inhibitors; X-ray co-
structures with T. cruzi CYP51 were determined. 
Conclusion: The structures explain the 
compounds’ potency and selectivity. 
Significance: Structural information contributes to 
a better understanding of P450 inhibition and will 




Chagas disease, caused by the eukaryotic 
(protozoan) parasite Trypanosoma cruzi, is an 
alarming emerging global health problem with 
no clinical drugs available to treat the chronic 
stage. Azole inhibitors of sterol 14α-
demethylase (CYP51) were proven effective 
against Chagas, and antifungal drugs 
posaconazole and ravuconazole entered clinical 
trials in Spain, Bolivia and Argentina. Here we 
present the X-ray structures of T. cruzi CYP51 
in complexes with two alternative drug 
candidates, pyridine derivatives (S)-(4-
chlorophenyl)-1-(4-(4-(trifluoromethyl)phenyl)- 
piperazin-1-yl)-2-(pyridin-3-yl)ethanone (PDB 
code UDO) and N-[4-(trifluoromethyl)phenyl]-
N-[1-[5-(trifluoromethyl)-2-pyridyl]-4-piperi-
dyl]pyridin-3-amine (UDD). These compounds 
have been developed by Drugs for Neglected 
Diseases initiative (DNDi) and are highly 
promising antichagasic agents, both in cellular 
and in vivo experiments. Binding parameters 
and inhibitory effects on sterol 14α-
demethylase activity in reconstituted enzyme 
reactions confirm UDO and UDD as potent and 
selective T. cruzi CYP51 inhibitors. 
Comparative analysis of the pyridine- and 
azole-bound CYP51 structures uncovers the 
features which make UDO and UDD T. cruzi 
CYP51 specific. The structures suggest that 
while precise fit between the shape of the 
inhibitor molecules and T. cruzi CYP51 active 
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site topology underlies their high inhibitory 
potency, a longer coordination bond between 
the catalytic heme iron and the pyridine 
nitrogen implies weaker influence of pyridines 
on the iron reduction potential, which may be 
the basis for the observed selectivity of these 
compounds towards the target enzyme versus 
other CYPs, including human drug-
metabolizing P450s. The findings might pave 
the way for the development of novel CYP51-
targeted drugs with optimized metabolic 
properties that are highly needed for treatment 
of human infections caused by eukaryotic 
microbial pathogens. 
Sterol 14α-demethylase (CYP51) is a 
cysteine-coordinated hemoprotein, the cytochrome 
P450 (CYP) monooxygenase that catalyses the 
three-step reaction of oxidative removal of the 
14α-methyl group from cyclized sterol precursors 
(1,2). This P450 enzyme is found in all kingdoms 
of life (3,4), its reaction being essential for sterol 
biosynthesis (5). The products of the pathway, 
such as cholesterol in humans or ergosterol in 
fungi, are required for the integrity of the 
eukaryotic cell membrane and as metabolic 
precursors for a variety of signaling molecules. 
For more than 40 years CYP51 has successfully 
served as the major target for antifungal azoles (6-
8), and by now it is quite generally recognized as a 
promising therapeutic target in Trypanosoma (T.) 
cruzi as well (9). 
Endemic in South America, Chagas disease is 
a life threatening malignancy with only two drugs 
available for treatment (benznidazole and 
nifurtimox), both having low efficiency for the 
chronic stage that predominantly affects the heart 
and gastrointestinal tract. The disease is now 
becoming a severe global health problem, mainly 
due to human migration to other continents but 
also because of the broadening of the area of 
vector habitat: the triatomine insects that transmit 
the parasite (kissing bugs) now populate two-
thirds of the US land (10) and have been found in 
Asia, Australia and Africa. However, historically 
known as a disease of the poor, the infection does 
not attract the attention of pharmaceutical 
companies as being profitable, and for more than a 
century since its discovery the parasite has 
remained incurable. 
Finally, in 2011, after ~30 years of effort from 
academia on antifungal drug repurposing (11-17), 
two antifungal azoles, posaconazole and 
ravuconazole, entered clinical trials for Chagas 
disease (18). Some other azoles, such as the 
derivatives of the anticancer drug candidate 
tipifarnib (19,20) or FTI-2220 (21) were shown to 
display potent antiparasitic effects and are under 
investigation. Furthermore, an experimental T. 
cruzi CYP51 inhibitor VNI has been recently 
proven to cure both the acute and chronic forms of 
Chagas disease in mice (22). 
Similar to fungi, in T. cruzi the endogenously 
synthesized sterol molecules are C24-alkylated 
(ergosterol-like) and therefore they cannot be 
replaced in the parasite cells by host cholesterol 
(23). The shortage of endogenous sterols is 
especially harmful for the multiplying form of T. 
cruzi, intracellular amastigotes (24), the 
morphological form of the parasite that is 
prevalent at the chronic stage of infection. 
Accordingly, in amastigotes the expression level 
of the CYP51 gene is higher (25), and the effect of 
CYP51 inhibitors is about 3 orders of magnitude 
stronger than in the non-multiplying bloodstream 
trypomastigotes (22,25,26), the forms that are 
more relevant to the acute stage of infection and 
can be effectively treated with benznidazole. 
Depletion of endogenous sterols in T. cruzi due to 
CYP51 inhibition causes blebbing of the cellular 
membrane, mitochondrial swelling, alterations in 
endoplasmic reticulum and Golgi, nuclear 
envelope detachment, deterioration of internal 
membranes and ultimately results in cell lysis and 
death (27,28). 
T. cruzi CYP51, which has <25% identity to 
fungal orthologs, has been well characterized 
biochemically and structurally (25-27,29). First, 
the gene was cloned from the Tulahuen strain of 
the pathogen, the recombinant protein expressed in 
Escherichia coli and purified (29). We found that 
the T. cruzi CYP51 substrate preference towards 
the C4-double methylated eburicol (24-methylene-
dihydrolanosterol) is largely defined by a single 
amino acid residue in the B’ helix, I105 
(animal/fungi-like), versus the corresponding Phe 
in the plant-like CYP51 orthologs from T. brucei 
(30) and Leishmania (L.) infantum (31) that 
catalyze 14α-demethylation of C4-
monomethylated obtusifoliol and norlanosterol. 
Studies on CYP51 inhibition revealed that 
susceptibilities of the protozoan enzymes to 
antifungal drugs often differ significantly from 
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those of fungal CYP51 orthologs and led to 
identification of several novel experimental 
inhibitory scaffolds (26,27,32,33). Determination 
of X-ray crystal structures of T. cruzi (25,34), T. 
brucei (20,35) and L. infantum (31) CYP51s, 
ligand-free and complexed with several azole 
derivatives including 1,2,4-triazole posaconazole 
(25) and 1,3-imidazole VNI (35), and with the 
mechanism-based suicide substrate 14α-
methylenecyclopropyl-dihydrolanosterol (32) 
established the molecular basis for the CYP51 
catalytic conservation (36). To be able to perform 
its ancient biological function across phylogeny at 
very low sequence identity, this P450 enzyme has 
a highly rigid substrate binding cavity, which in 
turn serves as the foundation for its druggability 
(32,37). 
In the present work we tested T. cruzi CYP51 
as a potential target for two pyridine-based 
compounds, EPL-BS1246 (UDO) and EPL-
BS0967 (UDD), which have been identified as 
strong antiparasitic agents in cellular T. cruzi 
experiments and display high potency in vivo in a 
stringent mouse model of Chagas disease. We 
report UDO and UDD binding parameters, 
inhibitory effects on sterol 14α-demethylation 
activity and co-structures with T. cruzi CYP51, 
comparing them with the CYP51 complexes with 
posaconazole and VNI (Fig. 1). The structures 
provide valuable information regarding the 
features that contribute to the potency of these two 
new CYP51 inhibitors and their selectivity 
towards the T. cruzi enzyme ortholog. Particularly, 
they show that the peculiarities observed in the 
enzyme spectral responses to UDO/UDD binding 
reflect a longer coordination bond between the 
ferric heme iron and heterocyclic pyridine (vs. 
azole) nitrogen, which is likely to underlie higher 
specificity because weakened Fe-N interaction 
would enhance the role of other, non-bonded 
protein-ligand contacts. This is the first report of 
highly potent T. cruzi CYP51 inhibitors of non-
azole nature, and we believe that the information 
gained in this study will facilitate structure-based 
design of pathogen-specific drugs with optimized 
metabolic properties, which will have little or no 
effect on human drug-metabolizing P450s. 
 
EXPERIMENTAL PROCEDURES 
Testing UDO (EPL-BS1246) and UDD (EPL-
BS0967) as antiprotozoan drug candidates. 
The compounds – UDO and UDD were 
synthesized as part of a Drugs for Neglected 
Diseases initiative (DNDi) drug discovery 
program to develop new treatments for Chagas 
disease and are the result of structure-activity 
relationship (SAR) optimization of plant fungicide 
fenarimol (pyrimidine derivative), which was 
found to have moderate in vitro activity against T. 
cruzi (38). The synthesis was carried out by 
analogy to the methods reported in (38,39). Both 
compounds were prepared by a short synthetic 
sequence from readily available precursors. 
Racemic-UDO was synthesized in 5 steps (3 
contiguous) from key building blocks 3-
fluoropyridine, 4-chlorophenylacetonitrile and 1-
[4-(trifluoromethyl)phenyl]piperazine in high 
overall yield (45%). Chiral resolution was 
achieved using supercritical fluid chromatography 
(SFC) after which the S-enantiomer was identified 
as most active in in vitro assays. UDD was 
constructed in 4 steps, 12% overall yield, from 3-
amino pyridine, piperidin-4-one and 2-chloro-5-
(trifluoromethyl)pyridine. As a trigonal N-
centered ligand, UDD is achiral and no further 
manipulation of the final product was required. 
Cellular T. cruzi assay - The assay was 
performed using the β-galactosidase expressing 
Tulahuen T. cruzi as described previously (40). 
Briefly, L6 cells were plated into 96 well, flat-
bottom tissue culture plates and incubated at 37°C 
in 5% CO2 for 24 h to allow cells to adhere. T. 
cruzi trypomastigotes were then added at a 
multiplicity of infection of 3, and plates were 
incubated for a further 48 h to allow infection to 
establish. Extracellular trypomastigotes were then 
removed and compounds were added in seven-
point serial dilutions performed in triplicate. After 
96 h of incubation with the compounds, 
chlorophenol red-fl-D-galactopyranoside (CPRG, 
Roche) was added; a color change following 
catabolization of the reagent by viable T. cruzi was 
observed and absorbance was read at 530 nm 
using a Dynex microplate reader. 
Cellular L. donovani assay – The assay was 
performed using the L. donovani MHOM/ET/67/ 
L82 strain. Primary peritoneal mouse macrophages 
were infected at a multiplicity of infection of 1 to 
10 with Leishmania parasites. Compounds were 
added after 2 hours of infection. Parasite 
multiplication was compared to untreated-infected 
controls (100% growth) and uninfected controls 
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(0% growth). After 5 days incubation, parasite 
burdens (mean number of amastigotes per 
macrophage) were microscopically assessed after 
staining the cells with a 10% Giemsa solution. The 
results were expressed as % reduction in parasite 
burden compared to untreated control wells. 
Anti-T. cruzi activity in vivo - Female Swiss 
mice ~8 weeks old were obtained from the Animal 
Resources Centre (Perth, Western Australia). All 
animal experiments were carried out with approval 
of the Animal Ethics Committee of Murdoch 
University as described (38). Briefly, compounds 
were suspended in a hydroxypropylmethyl-
cellulose suspension vehicle (0.5% w/v hydroxyl-
propylmethylcellulose + 0.4% v/v Tween 80 + 
0.5% v/v benzyl alcohol in deionized water) and 
given by oral gavage. Induction of acute T. cruzi 
infection was achieved by infecting mice with 
50,000 Tulahuen trypomastigotes via intraperito-
neal (ip) injection (5 mice per group). Compound 
administration was commenced on day 8 post 
infection and continued daily for 20 days. 
Parasitemia was determined by collection of blood 
by tail prick and counting live trypomastigotes 
under the microscope using a Neubauer 
hemocytometer. Efficacy was monitored by 
comparison of parasitemia levels in compound 
treated vs. vehicle only treated groups. If 
parasitemia levels were no longer detectable in the 
blood following compound treatment, animals 
were immunosuppresed with cyclophosphamide 
10 days after the treatment cessation. 
Cyclophosphamide was administered ip at 50 
mg/kg/day in three cycles; each cycle comprised 4 
days treatment followed by 3 days rest. 
Parasitemia was determined by collection of blood 
as detailed above; parasitological cure was 
confirmed by PCR on tissue samples (38). More 
extended description of in vivo data will be 
published elsewhere. 
Inhibition of human drug-metabolizing CYPs - 
Inhibition of hepatic cytochromes P450 was 
assessed in human liver microsomes using a 
substrate specific approach monitoring metabolites 
formed by each specific CYP enzyme. Metabolic 
reactions included phenacetin-O-deethylation 
(1A2), tolbutamide methylhydroxylation (2C9), S-
mephenytoin 4'-hydroxylation (2C19), dextrome-
thorphan O-deethylation (2D6), and testosterone-
6-β-hydroxylation (3A4). Each substrate was 
added at a concentration less than or equal to the 
Km for the metabolic pathway, and microsomal 
protein concentrations and assay incubation times 
were optimized for each reaction to ensure linear 
metabolite formation based on initial rates (Table 
1). Microsomes were suspended in phosphate 
buffer and incubated at 37ºC in the presence of 
probe substrates. Reactions were initiated by the 
addition of an NADPH-regenerating buffer system 
and were quenched at appropriate times using 
acetonitrile. Samples were centrifuged and 
concentrations of metabolites assessed by LC/MS. 
The IC50 was taken as the concentration at which 
there was a 50% reduction in the rate of metabolite 
formation relative to the metabolite formation rate 
in the absence of inhibitor. Additionally, effects of 
UDO and UDD on CYP3A4 were compared with 
the effects of posaconazole and VNI (Fig. 1) using 
a commercial kit (BD Biosciences Screening Kit) 
as described (22), drug concentration range 16000-
2.4 nM. IC50 for the manufacturer’s positive 
control inhibitor ketoconazole at these conditions 
was ~ 8 nM). 
 
Testing UDO (EPL-BS1246) and UDD (EPL-
BS0967) as CYP51 inhibitors. 
Protein engineering, expression and 
purification - For functional studies, including 
ligand binding and enzymatic activity assays, the 
full-length CYP51 expression constructs, designed 
as described in (29,31), GenBank IDs AY856083 
and EF192938 for T. cruzi and L. infantum 
CYP51, respectively, were used. For 
crystallization, we utilized the T. cruzi CYP51 N-
terminal truncated construct where the membrane 
anchor sequence (first 31 residues upstream of 
P32) was replaced with the 5-amino acid sequence 
fragment MAKKT- described in (25) for co-
crystallization with posaconazole. In all cases the 
CYP51 genes were His-tag-engineered at the C-
terminus to facilitate purification, subcloned into 
the pCW expression vector at Nde I (5’-) and Hind 
III (3’) sites and expressed in E. coli strain 
HMS174(DE3) (Novagen). For T. cruzi CYP51, 
purification procedure included sequential 
chromatography on nickel nitrotriloacetate-
agarose (Qiagen) and carboxymethyl-Sepharose 
(Sigma) (29). L. infantum CYP51, human CYP51 
and cytochrome P450 reductase were purified as 
previously reported (30,31,41). For crystallization 
purposes complexes with the inhibitors were 
obtained by saturating T. cruzi CYP51 with the 
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compound during the last purification step by 
adding a 10 mM DMSO stock solution of the 
inhibitor to the washing and elution buffers, final 
concentration being 20 µM. 
Spectral ligand binding assay – All spectra 
were recorded at 22ºC on a dual-beam Shimadzu 
UV-240IPC spectrophotometer. The P450 
concentration was determined from the Soret band 
intensity of the reduced CO complexes using 
visible absorption difference spectroscopy, Δε450–
490 = 91 mM
-1cm-1 (42). Spectral titrations were 
carried out at 0.4 µM P450 concentration in a 50 
mM K-phosphate buffer, pH 7.4, containing 200 
mM NaCl and 0.1 mM EDTA. The optical path 
length was 5 cm. Ligand binding was monitored as 
a red shift in the Soret band maximum reflecting 
coordination of the heterocyclic nitrogen to the 
P450 heme iron (26). Difference spectra were 
generated by recording the P450 absorbance in a 
sample cuvette versus the absorbance in a 
reference cuvette, both containing the same 
amount of the protein. Compounds were added to 
the sample cuvette in the concentration range 0.1 - 
2.0 µM from 0.2 mM stock solutions in DMSO. 
The titration step was 0.1 µM. At each step, the 
corresponding volume of DMSO was added to the 
reference cuvette. The apparent dissociation 
constants of the enzyme-inhibitor complexes (Kd) 
and the maximum spectral change (ΔAmax) were 
calculated using a quadratic function for tight 
binding ligands by fitting the data for the ligand-
induced spectral change (peak to trough 
absorbance changes in the difference spectra 
(ΔA)) versus total ligand concentration to the 






where [L] and [E] are the concentrations of the 
ligand and the enzyme used for the titration, 
respectively. 
CYP51 inhibition assay - Enzymatic activity 
of T. cruzi, L. infantum and human CYP51s was 
reconstituted in vitro as described previously 
(29,31,41), using eburicol, obtusifoliol and 
lanosterol, respectively, as the substrates. Briefly, 
the reaction mixture contained 1 µM CYP51, 2 
µM cytochrome P450 reductase (CPR), 100 µM 
dilauroyl-α-phosphatidylcholine, 0.4 mg/ml 
isoctrate dehydrogenase and 25 mM sodium 
isocitrate in 20 mM MOPS (pH 7.4), 50 m M KCl, 
5 mM MgCl2 and 10% glycerol. After addition of 
the [3H]-radiolabeled sterol substrate (~2,000 
cpm/nmol, final concentration 50 µM) the mixture 
was preincubated for 5 min at 37 ºC in a shaking 
water bath (GCA Precision Scientific). The 
reaction was initiated by addition of 100 µM 
NADPH and stopped by extraction of the sterols 
with ethyl acetate. The reaction products were 
dried, dissolved in methanol and analyzed by a 
reverse-phase HPLC system (Waters) equipped 
with β-RAM detector (INUS Systems, Inc.) using 
a Nova Pak C18 column (particle size 4 µM, 3.9 x 
150 mm) and linear gradient 
water:acetonitrile:methanol (1.0:4.5:4.5) (solvent 
A) methanol (solvent B) at a flow rate 1 ml/min. 
At these conditions the retention time for eburicol, 
obtusifoliol and lanosterol was 26, 23, and 25 min, 
respectively. Retention time for the reaction 
intermediates, 14α-alcohol and 14α-aldehyde 
derivatives of obtusifoliol (30) (seen in Fig. 3, L. 
infantum CYP51), was 10 and 12 min, 
respectively. Potencies of UDO and UDD to 
inhibit T. cruzi, L. infantum and human CYP51 
were compared as inhibition of enzymatic activity 
in a one hour reaction (25,26), posaconazole 
serving as positive control. 
Crystallization, Data Collection and Structure 
Determination - The co-crystals were obtained by 
hanging drop vapor diffusion. The 250 µM protein 
solution in 20 mM K-phosphate buffer, pH 7.2, 
containing 200 mM NaCl, 0.1 mM EDTA, 1 mM 
dithiothreitol, 10% glycerol and 8 mM Cymal 4, 
saturated with the inhibitor as described above, 
was mixed with the equal volume of a precipitant 
solution containing 50 mM K-phosphate buffer, 
pH 7.6, 0.2 M magnesium chloride hexahydrate 
and 25% (w/v) PEG 4000 and was equilibrated 
against the precipitant solution at 22ºC. Crystals 
were prescreened using Bruker Microstar 
microfocus rotating-anode X-ray generator/Pro-
teum PT135 CCD area detectors, and those that 
diffracted to ~3.0Å resolution were subsequently 
used for the data collection at a synchrotron 
(Advanced Photon Source, Argonne National 
Laboratory, IL). Data were collected at LS-CAT, 
beamline 21ID-F. The diffraction images were 
integrated using Mosflm (44) and scaled with 
Aimless (CCP4 Program Suite 6.3.0 (45)) in the 
P3(1)21 space group to resolutions of 2.8 Å 
(UDO) and 2.9 Å (UDD). Solvent content was 
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estimated with Matthews probability calculator. In 
both cases a single solution with one molecule in 
the asymmetric unit was found with PhaserMR 
using posaconazole-bound T. cruzi CYP51 
structure (PDB code 3K1O) as the search model. 
Iterative models of the protein-inhibitor complexes 
were built and refined using COOT (46) and 
Refmac (47) in CCP4 (45). The statistics for data 
collection, refinement, and validation are shown in 
Table 2. The protein chain is seen from residue 28 
(A in the N-terminal MAKKT- sequence) to 478 
(of 482) for T. cruzi CYP51-UDO and from 
residue 29 to 478 for T. cruzi CYP51-UDD. The 
electron density for both UDO and UDD was well 
defined (Fig. 2), showing single orientation of the 
inhibitor molecule within the enzyme binding 
cavity and full occupancy. The coordinates and 
structure factors have been deposited at the Protein 




As shown in Fig. 1, UDO and UDD are highly 
efficient against T. cruzi, both in cellular 
experiments and in vivo. The compounds were 
identified upon testing of a number of 
pharmacologically optimized derivatives of 
pyrimidine-based fungicide fenarimol and both 
contain a heterocyclic (pyridine) ring with a basic 
nitrogen atom, thus suggesting a possibility of its 
coordination to the P450 heme iron. On the other 
hand, their inhibitory effects on all five major 
human drug-metabolizing P450s (48) are very 
weak (Table 1), and the whole organism primary 
in vitro screen that was used to drive the discovery 
process is mechanistically nonspecific. Therefore, 
it was of special interest to verify whether they 
inhibit the parasite CYP51. 
CYP51 spectral responses to ligand 
binding. Recombinant CYP51s are usually 
purified in the hexacoordinated low spin form, 
with the Soret () band absorbance maximum at 
~417 nm (3,29-31,49), the oxygen atom from a 
water molecule serving as the sixth (distal axial) 
ligand for the ferric heme iron (50). If a stronger 
ligand replaces the water molecule in the iron 
coordination sphere, the Soret maximum shifts to 
the longer wavelength (red shift, or type II spectral 
response). Consequently, in the difference spectra 
a trough and a peak appear on the left and the right 
side of an isosbestic point, respectively. 
Accordingly, when the iron in T. cruzi CYP51 
becomes coordinated to an azole ring nitrogen, the 
trough/isosbestic point/peak in the difference 
spectra emerge at 407/419/428 nm in the case of 
imidazole N3 (VNI) (Fig. 3D) and at 392/415/425 
nm in the case of triazole N4 (posaconazole) (Fig. 
3C). The difference spectra elicited in T. cruzi 
CYP51 by UDO and UDD, however, revealed the 
trough at 389 nm, isosbestic point at 411 nm and 
peak at 423 and 422 nm, respectively (Fig. 3A,B). 
The Soret band absolute absorbance maximum 
was red-shifted only to 421 nm (vs. 424 nm in 
VNI-bound and 423 nm in posaconazole-bound 
CYP51 (Table 3)), hence suggesting weaker 
interaction of the sixth ligand with the heme iron. 
On the other hand, the apparent Kd values 
calculated from T. cruzi CYP51 spectral responses 
to UDO (19 nM) and UDD (32 nM) were found 
comparable to those obtained for VNI and 
posaconazole (Table 3), the titration curves all 
showing saturation at about equimolar ratio 
inhibitor/enzyme (Fig. 3A). Thus, although the 
pyridine ring nitrogen can be characterized as a 
weaker iron-coordinating atom, based on the 
apparent Kd values, both compounds seemed to 
form strong complexes with T. cruzi CYP51. 
Interestingly, for L. infantum CYP51, whose 
spectral responses to the binding of UDO and 
UDD are quite similar in their shape (Fig. 3E,F), 
the calculated Kds were about one order of 
magnitude higher, 156 nM and 419 nM, 
respectively (Table 3), while the responses of the 
human enzyme ortholog suggested tight binding 
with the position of the peak in the difference 
spectra red-shifted to 424 nm (Fig. 3G,H) and the 
apparent Kds of 69 nM (UDO) and 26 nM (UDD) 
(Table 3). 
Inhibition of CYP51 activity in vitro. As 
discussed previously (26,37), sensitivity of the 
CYP51 reaction reconstituted in vitro is limited by 
a) the affinity of the CYP51-CPR complex 
formation (Kd ≈1 µM, so that further lowering the 
P450 concentration sharply decreases its turnover 
rate) and b) by very poor solubility of the sterol 
substrates which in turn does not allow the use of 
higher substrate excess over the enzyme. 
Therefore, in order to identify most potent CYP51 
inhibitors, in our standard conditions we use a one 
hour CYP51 reaction, the molar ratio 
inhibitor/enzyme/substrate being 2/1/50 
(20,25,34). At these conditions, in the absence of 
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inhibitors all the substrate is converted into the 
product, and most compounds (even amongst 
those displaying complete inhibition of the initial 
rate of the reaction) show little inhibitory effect (9) 
because over time they are replaced in the enzyme 
active center by substrate. 
-T. cruzi CYP51. UDO and UDD, however, 
completely inhibit T. cruzi CYP51 activity under 
these conditions (Fig. 4A,B). Moreover, lowering 
the concentration of T. cruzi CYP51 in the 
reaction mixture to 0.2 µM (which leads to about a 
40-fold decrease in the enzyme turnover) did not 
reveal any product formation at inhibitor/enzyme 
molar ratios ≥1 in all three cases (not shown). 
These data indicate that although based on the 
position of the Soret band maximum Fe-pyridine 
interaction can be characterized as weaker, 
potencies of these compounds to inhibit the T. 
cruzi enzyme activity are similar to that of 
posaconazole and agree with the low apparent Kd 
values. 
-L. infantum CYP51. The inhibitory effects of both 
compounds on the activity of L. infantum CYP51 
are slightly weaker, as 32% and 60% of substrate 
conversion is observed at a two-fold molar excess 
of UDO and UDD, respectively (Fig. 4A); the 
molar ratios inhibitor/enzyme required to slow 
down the L. infantum CYP51 reaction 2-fold are 
1.5 and 2.8 (Fig. 4C). Again, lower inhibitory 
potencies correlate with the lower apparent 
binding affinities and are in agreement with the 
weaker antiparasitic effect of UDD against 
leishmania cells (Fig. 1). 
-Human CYP51. The activity of the human 
enzyme, however, is not affected at these 
conditions: a 180-fold molar excess of UDO and a 
35-fold molar excess of UDD were necessary to 
achieve a 2-fold inhibition (Fig. 4D). Thus, 
regardless of the low apparent Kds calculated from 
the titration curves, both compounds (especially 
UDO) inhibit human CYP51 much weaker than 
the parasitic counterparts.  
Interestingly, relative potencies of UDO and 
UDD to inhibit human and leishmania CYP51s are 
reversed: while UDO is roughly 2-fold stronger 
than UDD as the inhibitor of L. infantum CYP51, 
for the human enzyme UDD has a 5-fold higher 
potency than UDO. In order to better understand 
the molecular basis for the compounds 
potency/selectivity, we determined their X-ray 
structures in complexes with T. cruzi CYP51. 
Structural characterization of the CYP51-
inhibitor complexes. 
-Inhibitor binding mode. As expected for type 
II P450 ligands, each of the inhibitors interacts 
with the heme, its pyridine ring nitrogen forming a 
coordination bond to the heme iron. The pyridine 
rings are in favorable conformation, perpendicular 
to the heme plane. Yet, in both cases the Fe3+-N 
coordination bond is rather long, 2.31Å for UDO 
and 2.34Å for UDD (Fig. 2). This is about 0.3 Å 
longer than the coordination bond in the CYP51 
complexes with imidazoles (2.0-2.04Å in VNI 
[3gw9](35), tipifarnib derivative JFK [3tik] (20) or 
NEE [4h6o] (34),) and more than 0.2Å longer than 
the coordination bond in the CYP51 complexes 
with triazoles (2.07-2.15 Å) [3k1o], [3khm] (25) 
or [3l4d] (31) (see examples in Table 4). A weaker 
coordination bond explains the smaller red shift in 
the Soret band absorbance maximum and 
apparently reflects the decrease in the 
elecronegativity of the iron-coordinating atom 
(imidazole > triazole > pyridine). Overall, 
orientation of UDO and UDD within the CYP51 
binding cavity is similar to VNI and almost 
identical to that of posaconazole, with the longer 
(two-ring) arm of each compound being directed 
towards the substrate access channel entrance 
(Fig.5. A,B,C). 
-Overall CYP51 structure. Similar to what was 
observed previously for complexes with imidazole 
and triazole inhibitors (20,25,34,35) and the 
substrate analog MCP (32), binding of UDO or 
UDD does not induce any significant 
conformational changes at the overall structure 
level (Fig. 5D). The root mean square deviations 
(rmsd) for Cα atoms of 3zg2 and 3zg3 relative to 
3k1o (posaconazole bound T. cruzi CYP51) are 
only 0.535Å and 0.567Å, respectively, and 
between the two structures reported here the rmsd 
is 0.453 Å. As appears to be common for CYP51s, 
the highest deviations are displayed by a few 
residues at the N- and C-termini, the GH loop 
region as well as by the structural elements 
surrounding the entrance into the substrate access 
channel, especially the FG loop area. While the 
functional role of the GH loop flexibility in 
CYP51s remains unclear, the movements around 
the F’’ helix, which forms the upper portion (the 
lid) of the substrate channel entrance, may reflect 
opening and closing of the channel that takes place 
in vivo, upon binding of the bulky sterol molecule 
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and release of the 14α-demethylated reaction 
product back into the microsomal membrane. The 
other secondary structural elements, including the 
side chains of the residues contacting the inhibitor, 
remain in very similar positions in both structures 
(the stereoview of their superimposition can be 
seen in Fig. 6C). 
-UDO-CYP51 complex. UDO (MW 460, 16.5 
Å in length) has the molecular volume of 549 Å3 
(Accelrys), which is considerably smaller than the 
volume of Pos (673 Å3, 25.5 Å in length (25). 
Nevertheless, it forms van der Waals contacts with 
18 amino acid residues (the distance <4.5 Å) of the 
enzyme (Fig. 6A). Six of these residues, V102, 
Y103, M106, F110, A115 and Y116, are from the 
B’ helix and B’/C loop, the major CYP51 
substrate recognition site. In the sterol-bound form 
of the enzyme, these secondary structural elements 
encircle the whole skeleton of the substrate 
molecule from its -side (32). L127 is from helix 
C (CYP51-specific area of the binding cavity). In 
the substrate-bound CYP51 it interacts with the 
distal portion of the sterol arm (C26-C28). 
Altogether, these seven residues flank the inhibitor 
from the upper portion of the enzyme active site. 
Helix I forms the distal wall of the cavity and 
provides 4 residues, A287, F290, A291, and T295. 
L356, M358 and M360 are from the K/1-4 loop, 
and M460 is from the tip of the 4 hairpin, which 
also forms the bottom of the entrance into the 
substrate access channel. Again, the majority of 
these residues are involved into the interaction 
with the substrate (32) and reveal a high level of 
conservation within phyla, (36) thus providing a 
potential molecular basis for phyla-specificity of 
CYP51 inhibitors. Finally, P210, V213 and F214 
(F’’ helix) are from the lid of the substrate channel 
entrance. The involvement of these three residues 
is specific for UDO binding (left upper corner of 
Fig. 6A). 
-UDD-CYP51 complex. UDD (MW 466, 15.6 
Å in length) is even slightly smaller than UDO 
(molecular volume 535 Å3), but it also forms van 
der Waals contacts with 18 amino acid residues, 
and again, only three of those residues, I105 (B’ 
helix), L130 (C helix) and M284 (I helix), are 
UDD-specific (Fig. 6B). L130 and M284 are seen 
in the right lower corner of Fig. 6B, and 105 is the 
residue that defines the T. cruzi CYP51 substrate 
preference towards the C4-double methylated 
sterol substrates (29). In the T. cruzi CYP51 
complex with UDD I105 is involved into the 
interaction with the inhibitor because, as it can be 
seen in Fig. 5A, the UDD molecule, whose 
structural skeleton is even more rigid than that of 
UDO, is slightly more crescent shaped. Another 
feature, specific to UDD T. cruzi CYP51 co-
structure, is that the trifluoromethylbenzene ring 
of the inhibitor wedges between the heme plane 
and B’C loop, pushing away Y116 (Fig. 6D, 
right). Due to its offset position (4.02 Å) from the 
hydroxyl group of the porphyrin ring D 
propionate, the OH of Y116 cannot donate a 
hydrogen bond to the heme as it does in the 
enzyme complex with UDO (Fig. 6D, left) as well 
as with posaconazole (25). Displacement of the 
Y116 side chain was observed in the co-structures 
of T. cruzi CYP51 with VNF (25) and NEE (34). 
As discussed previously (35,36), disruption of this 
heme support from the protein moiety may also 
add to the UDD inhibitory potency. Assuming that 
the inhibitor molecule in human CYP51 adopts the 
orientation similar to that in the complex with T. 
cruzi CYP51, relatively stronger inhibition of the 
enzyme by UDD might also be due to disruption 
of the heme support from the corresponding Y 
(Y145 in human CYP51). 
To summarize, binding of both UDO and 
UDD to T. cruzi CYP51 produces the enzyme-
inhibitor complexes that display long Fe-N 
coordination bonds, extensive van der Waals 
interactions with the amino acid side chains of the 
active site and do not require structural 
rearrangements in the protein. 
 
DISCUSSION 
It has been known for years that cytochromes 
P450 are inhibited by heterocyclic compounds, 
with two components being important for the 
strength of the inhibition: 1) coordination of a 
basic heterocyclic atom with the heme iron (which 
lowers the P450 potential to be reduced) and 2) 
weaker but multiple interactions of the non-
coordinated portion of the inhibitor molecule with 
the protein moiety (51). To date, within this type 
of P450 inhibitors, azoles have certainly remained 
the most potent, 1,3-imidazole and 1,2,4-triazole 
derivatives serving as clinical antifungal drugs and 
agricultural fungicides (CYP51 inhibition), and 
yet, especially within the last decade, becoming 
quite notorious for their off-target activity 
(particularly, inhibition of other human CYPs 
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(48,52-57), and relatively high propensity to 
induce resistance (58,59). Although several 
heterocyclic compounds other than azoles have 
been identified as T. cruzi CYP51 inhibitors, their 
inhibitory effects on the enzyme activity in vitro 
are much weaker, e.g. ChemDiv C155-0123 or 
indomethacin–pyridines are quite easily replaced 
by substrate during the time-course of the CYP51 
reaction (9). To our knowledge, this is the first 
report of non-azole type II ligands whose potency 
to inhibit CYP51 activity is comparable with that 
of the most effective azoles (Fig. 4A). 
This structural study suggests that because of 
weaker interaction between the heme iron and 
pyridine nitrogen of the inhibitors, the strength and 
selectivity of UDO and UDD must mainly derive 
from the fine topological fit between the rigid 
small molecules and T. cruzi CYP51 binding 
cavity. Thus, being much smaller than 
posaconazole, both UDO and UDD form contacts 
with as many as 18 amino acids within the T. cruzi 
CYP51 active site. Amongst them, the residues 
from the C-terminal portion of the B’/C loop, helix 
C and the N-terminal helix I (Fig. 6A,B) might be 
of special value to ensure CYP51-selectivity 
because this part of the cavity appears to be 
CYP51-specific (31,32). For comparison, 
posaconazole forms contacts with 24 amino acids 
of T. cruzi CYP51. Yet only 13 of these are from 
the CYP51 active site cavity, while the 11 others 
are located on the protein surface, encircling the 
entrance into the substrate access channel (25). 
Mutations in some of these residues were shown to 
be responsible for the development of CYP51-
based posaconazole resistance in fungi (25). 
Besides, it is the synthesis of the posaconazole 
long arm (which in the enzyme/inhibitor complex 
protrudes through the channel entrance above the 
protein surface) that makes the drug highly 
expensive (60). VNI (35), whose molecular 
volume is comparable with UDO/UDD, forms 
contacts with only 15 protein residues; its 
potency/selectivity towards trypanosomal 
CYP51s, being strengthened by the hydrogen bond 
network that connects, via the inhibitor 
carboxamide fragment, the B’ and I helices in the 
protozoan enzymes, but is probably not formed in 
the complex of VNI with the human CYP51 (9). 
The notion that good fit between the non-
ligated portions of UDO/UDD and the topology of 
the CYP51 binding cavity should play a greater 
role in these complexes is also supported by the 
results on inhibition of L. infantum and human 
CYP51s. In the L. infantum ortholog, which has a 
single amino acid difference from T. cruzi CYP51 
within the active site, F104 (corresponding to I105 
in T. cruzi (31)) protrudes deeper into the substrate 
binding cavity. In the L. infantum ortholog (one 
amino acid difference from T. cruzi CYP51 within 
the active site), the phyla-specific F104 
(corresponding to T. cruzi CYP51 I105) protrudes 
deeper into the substrate binding cavity. When L. 
infantum and T. cruzi CYP51 structures are 
superimposed, it is seen that this residue comes 
into a close contact with UDO and especially with 
UDD (see Fig. 7A as an example). The distance 
F103-UDO (2.1Å) is too short, and would induce a 
strongly repulsive van der Waals potential 
between the contacting atoms. Hence, in the 
complex with L. infantum CYP51, the inhibitor 
molecule must adopt a slightly different position. 
As a result, the geometric fit is impaired, and the 
inhibitory potency decreases (Fig. 4A,C), which is 
also reflected in the lower binding affinity. On the 
contrary, the inhibitory effects of UDD and 
especially UDO on human CYP51 (where 12 of 
the 25 amino acids whose side chains line the 
surface of the active site cavity differ from those 
in T. cruzi CYP51 (Fig. 7B)) are negligible (Fig. 
4D), although their binding affinities appear to be 
very high. This apparent discrepancy (low 
apparent Kds yet weak inhibition) was observed 
before for other inhibitory scaffolds (e.g. 
posaconazole, VNF  (25), VNI (35))  and can 
result from the differences in the central portion of 
the human CYP51 I helix (25,37) that has a low 
energy loop-like region preceded by a leucine 
residue (L310) instead of  bulkier F290 in the 
parasitic CYP51s (Fig. 7B). Larger space 
combined with the elevated flexibility of the P450 
core helix in close proximity to the heme iron area 
might diminish steric hindrances for a heterocyclic 
ring of an inhibitor to approach the heme, but will 
not be helpful in holding it within the P450 active 
center tight enough to prevent its replacement with 
the substrate in the enzymatic reaction. 
Finally, a weaker coordination bond between 
the catalytic heme iron and the less electronegative 
nitrogen of the pyridine ring implies less negative 
impact of UDO and UDD on the P450 reduction 
potential. This provides a reasonable explanation 
for the observed weak influence of UDO and UDD 
T. cruzi CYP51 complexes with UDO and UDD 
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on the activity of the five major human drug-
metabolizing P450s (Fig. 1, Table 1), a feature 
highly desirable for any new chemotherapeutic 
agents as it decreases the risk of potential in vivo 
toxicity, particularly due to adverse drug-drug 
interactions (48). 
To conclude, UDO and UDD are promising 
new drug candidates for Chagas disease 
chemotherapy. Although their testing against other 
T. cruzi strains (which were recently shown to 
display high variability in their CYP51 genes (28)) 
is required prior to proceed to clinical trials, the 
compounds represent a valuable alternative as a 
new CYP51 inhibitory chemotype. The structural 
information gained in this study will provide 
guidance on the options for the scaffolds further 
improvement and analysis of their structure-
activity relations. More general, the data suggest 
that balancing the impact of heme-heterocycle and 
apoprotein-ligand interactions may be highly 
helpful to minimize off-target activity of CYP51 
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FIGURE 1. Structural formulas and antiparasitic effects of pyridine derivatives EPL-BS1246 
(UDO) and EPL-BS0967 (UDD) in comparison with the antifungal drug posaconazole and an 
experimental T. cruzi CYP51 inhibitor VNI. EC50 – (effective concentration)50, drug concentration 
required to reduce cellular growth by 50%. ED50 (effective dose)50, drug regimen  required to reach 
parasitological cure in 50% of animals; IC50 (inhibitory concentration)50, drug concentration required to 
inhibit the activity of the enzyme by 50%. qd, once daily administration, bid , twice daily administration. 
*Data from (22); ** data from (38). 
 
FIGURE 2. 2Fo-Fc electron density map of T. cruzi CYP51 in complex with UDO and UDD 
weighted at 1.5 σ. The distance between Fe3+ and the pyridine ring nitrogen (Å) is marked with dashed 
purple line. 
 
FIGURE 3. Analysis of CYP51 interaction with different iron-coordinating ligands: absolute (upper) 
and difference (lower) spectra and binding curves (right side insets). Spectral responses of T. cruzi 
CYP51 to pyridine derivatives UDO (A) and UDD (B), triazole posaconazole (C) and imidazole VNI (D); 
L. infantum CYP51 to UDO (E) and UDD (F); and human CYP51 to UDO (G) and UDD (H). The 
titration experiments were performed in 5 cm optical path cuvettes at P450 concentration 0.4 μM; titration 
range 0.1 – 2 µM; titration steps 0.1 µM. The binding curves show absorbance changes per 1 cm optical 
path per 1 nmol P450.   
 
FIGURE 4. Inhibitory effects of UDO and UDD on CYP51 activity.  Eburicol, obtusifoliol and 
lanosterol, final concentration 50 µM) were used as substrates for T. cruzi, L. infantum and human 
CYP51s, respectively; molar ratio enzyme/substrate=1/50; 1 hour reaction (no substrate conversion was 
observed after a 5-min reaction in the presence of each of the compounds at 1/1 molar ratio 
inhibitor/enzyme). A. HPLC profiles of substrate (S) conversion by T. cruzi and L. infantum CYP51 
orthologs in the presence of a 2-fold molar excess of the inhibitors over the enzyme. Posaconazole was 
used as a control. I1, 14α-carboxyalcohol intermediate, I2, 14α-carboxyaldehyde intermediate; P, 14α-
demethylated CYP51 reaction product. B. T. cruzi;  C. L. infantum; D. human CYP51 activity at 
increasing molar excesses of UDO an UDD. 
 
FIGURE 5. Structural characterization of T. cruzi CYP51 complexes with UDO (salmon) and UDD 
(grey). A. Superimposition of UDO and UDD with posaconazole (yellow) in 3k1o. B. Superimposition of 
UDO and UDD with VNI (yellow) in 3gw9. C. Overall view of the protein (rainbow color, from blue N 
terminus to red C terminus) with the bound inhibitors. P450 orientation is the same as in A and B; 
semitransparent surfaces of UDO and UDD are shown. The surfaces of the inhibitors are shown as 
semitransparent mesh. D. Distal view of superimposed 3gj2 (salmon), 3gj3 (grey) and 3k1o (gold), ribbon 
diagram. In 3k1o, the structural elements forming the entrance into the substrate access channel are 
colored in green. 
 
FIGURE 6. Views of the T. cruzi CYP51 active site illustrating interactions with UDO (salmon 
colored carbon atoms) and UDD (grey colored carbon atoms). A. Binding of UDO. The inhibitor 
molecule is shown as a sphere model, the carbon atoms of the side chains of the inhibitor contacting 
amino acid residues are depicted as light blue stick models; the corresponding secondary structural 
elements are shown as semitransparent grey ribbons and numbered; the C-atoms of the heme are yellow. 
UDO-specific T. cruzi CYP51 residues are underlined. B. Binding of UDD (sphere model, grey colored 
carbon atoms). The carbon atoms of the side chains of the inhibitor contacting residues and the 
semitransparent ribbon of the corresponding secondary structural residues are colored in pink and 
numbered. UDD-specific T. cruzi CYP51 residues are underlined. C. Comparative location of the 
inhibitor-contacting residues in the superimposed T. cruzi CYP51 co-structures with UDO and UDD. 
P450 orientation is the same as in A, B. Stereo view. The side chains of the inhibitor contacting residues 
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remain in very similar positions, with only long arms of M106 and M460 being shifted to the right in the 
UDO structure to better accommodate piperazinyl ring of the inhibitor. D. While both conserved in the 
CYP51 family heme supporting hydrogen bonds, between the hydroxyl Y103 and the porphyrin ring A 
propionate as well as between Y116 and the porphyrin ring D propionate, are preserved in the T. cruzi 
CYP51 complex with UDO, binding of UDD requires wedging of its aromatic ring between Y116 and the 
heme plane, which results in the Y116 OH - porphyrin ring D hydrogen bond disruption. 
 
FIGURE 7. Structural explanation for UDO/UDD pathogen-selectivity. A. F104 in the L. infantum 
CYP51 structure (3l4d) relative to I105 in the superimposed T. cruzi CYP51 (3zg3). At 72% average 
amino acid sequence identity, L. infantum and T. cruzi have only one amino acid difference in the 
residues whose side chains line the surface of the substrate binding cavity. B. Twelve amino acid 
differences inside the substrate binding cavity in T. cruzi (3zg2) and human (3ld3 (61)) CYP51s. UDO, 
UDD, the heme and 6 iron coordination bonds including the thiolate of C422 (the fifth (proximal) iron 
ligand) are shown. Color code for T. cruzi CYP51 structures is the same as in Fig.6. L. infantum and 
human CYP51s are colored in cyan and tan, respectively. 
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Table 1. Inhibitory effects of UDO and UDD on five major drug metabolizing CYPs determined in 
human liver microsomes 














1A2 phenacetin 40 phenacetin-O-deethylation 0.4 30 >20  >20 
2C9 tolbutamide 140 tolbutamide 
methylhydroxylation 0.4 20 
8.1 9 
2C19 S-mephenytoin 30 S-mephenytoin 4'-






deethylation 0.4 10 
20 4 
3A4 testosterone  50 testosterone-6-β-
hydroxylation 0.4 5 
>20 20 
a Substrate concentrations were ≤ Km values. 
b For each CYP, enzyme kinetic studies confirmed linear metabolite formation over this time period using the 
stated conditions. 
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T. cruzi   CYP51-inhibitor complex   EPL-BS1246 [UDO] [3zg2] EPL-BS0967 [UDD] [3zg3] 
Data collection   
Wavelength,  Å 0.9786 0.9786 
         Space group P3(1)21 P3(1)21 
         Cell dimensions   
               a, b, c, Å 63.699;63.699;223.263 62.849;62,849;222.395 
               α, β, γ,   90.00, 90.00, 120.00 90.00, 90.00, 120.00 
          Molecules per asymmetric unit 1 1 
          Solvent content, %  50.2 48.6 
          Resolution (last shell), Å 30-2.8 (2.9-2.8) 74-2.9 (3.0-2.9) 
          Rmerge (last shell) 0.043 (0.523) 0.085 (587) 
          I/σ (last shell)  69.4 (3.9) 21.3(2.4) 
          Completeness (last shell), % 99.3 (100) 99 (100) 
          Redundancy (last shell) 21.2 (6.9) 6.9 (7.1) 
Refinement   
          Resolution, Å 27.7-2.8 30.0-2.9 
          R-factor 0.268 0.248 
          R-free  0.282 0.289 
          Reflections used 12182 11342 
                  Test set size, % 5.3 5.3 
          Rms deviations from ideal geometry   
             Bond lengths,  Å 0.003 0.003 
             Bond angles,  1.23 0.716 
          Ramachandran plot   
              Residues in favorable regions (%) 95.7 96.8 
              Residues in allowed regions (%) 100 100 
             Outliers (%) 0 0 
Model   
          Number of atoms (average B-factor, Å) 3677 (58.1) 3639 (114.5) 
          Residues   
              protein 448 (58.6)  445 (115.3) 
              heme 1 (26.6) 1 (65.0) 
              Ligand 1 (38.9) 1 (90.2) 
          Water 13 (57.1) 6 (135.0) 
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Table 3. Apparent binding parameters and inhibition of T. cruzi, L. infantum and human CYP51 











Inhibitor/enzyme molar ratio 
required for a two-fold decrease 
in CYP51 activity (1 h reaction) 
T. cruzi – UDO 
T. cruzi – UDD 
T. cruzi – posaconazole 
T. cruzi – VNI 
 
L. infantum – UDO 
L. infantum – UDD 
L. infantum – posaconazole 
 
Human – UDO 













































T. cruzi CYP51 complexes with UDO and UDD 
 19
 
Table 4. Correlation between the spectral properties and the distances between the heme Fe and 
coordinating N atoms in the CYP51 complexes with imidazole, triazole and pyridine derivatives 
 
*the spectra are shown in Fig. 3.
Sixth (distal) ligand of the heme iron Absorbance (nm)* 
Difference spectrum  Fe-coordinating 
atom 
Compound [PDB ID] Soret band 







Imidazole N3 VNI [3gw9] 424 407 419 428 2.00 
Triazole N4 Posaconazole [3k1o] 423 392 415 426 2.07 












Water O HOH [3g1q] 417 - - - 2.93 

























T. cruzi (Tulahuen) amastigotes: EC50=7.5 nM
acute Chagas mouse model: ED50=20mg/kg/qd for 20 days
L. donovani: not tested 













T. cruzi (Tulahuen) amastigotes: EC50=15 nM
acute Chagas mouse model: ED50=20mg/kg/qd for 20 days
L. donovani: EC50 >10 µM (EC38=10 µM)













T. cruzi (Tulahuen) amastigotes: EC50=5 nM*
acute Chagas mouse model:  ED60=20mg/kg/qd for 20 days**
CYP3A4: IC50=0.120 µM 
VNI
T. cruzi (Tulahuen) amastigotes: EC50=1.3 nM*
acute Chagas mouse model: ED100=25mg/kg/bid for 30 days*
CYP3A4: IC50=0.405 µM
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